New oral anticoagulants: A view from the laboratory Journal Articles

abstract

• AbstractThe new oral anticoagulants are rapidly replacing warfarin for several indications. In contrast to warfarin, which lowers the functional levels of all of the vitamin K‐dependent clotting factors, the new agents target either factor Xa or thrombin. With targeted inhibition of coagulation, the new oral anticoagulants have pharmacological, biochemical, and clinical features distinct from those of warfarin. Focusing on laboratory perspectives, this article compares and contrasts the pharmacological and biochemical properties of thenew oral anticoagulants with those of warfarin and uses this information to speculate on the underlying mechanisms responsible for the clinical features that differentiate the new agents from warfarin. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.

authors

• Weitz, Jeffrey

status

• published 

publication date

• May 2012

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• Administration, Oral (MeSH)
• Animals (MeSH)
• Anticoagulants (MeSH)
• Blood Coagulation Factors (MeSH)
• Humans (MeSH)
• Immunology (Science Metrix)
• Vitamin K (MeSH)

published in

• American Journal of Hematology  Journal

keywords

• Administration, Oral
• Animals
• Anticoagulants
• Blood Coagulation Factors
• Humans
• Vitamin K

Digital Object Identifier (DOI)

• 10.1002/ajh.23139

PubMed ID

• 22407747

start page

• S133

end page

• S136

volume

• 87

issue

• S1